Episode Details

Back to Episodes

ICU Acquired Weakness

Season 1 Episode 105 Published 10 months, 1 week ago
Description

Today we’re talking about a topic that is relevant for all critical care physicians but under-examined: ICU Acquired Weakness. We are joined by two excellent guests to walk through a case and discuss the diagnosis, pathophysiology, prevention, and treatment of ICU Acquired Weakness. Check out our associated infographics and key learning points below.

Definition & Clinical Presentation

  • ICU-AW refers to new-onset, generalized muscle weakness that arises during critical illness, not explained by other causes.It typically presents as:
    • Symmetric, proximal > distal weaknessRespiratory muscle involvementPreserved cranial nerve functionNo sensory deficits in myopathy (sensory loss points toward neuropathy)
  • Differential Diagnosis Using Neuroanatomical ApproachAn anatomical approach (central → peripheral) helps localize the etiology weakness
  • CNS: trauma, stroke, encephalitis, seizuresAnterior horn cells: viral myelitis, motor neuron diseasePeripheral nerves: Guillain-Barré, vasculitis, critical illness polyneuropathy (CIP)Neuromuscular junction: myasthenia gravis, botulism, Lamber EatonMuscle: rhabdomyolysis, inflammatory or drug-induced myopathies, critical illness myopathy (CIM)
  • Subtypes of ICU-AW
  • Critical Illness Myopathy (CIM):
    • Muscle dysfunctionEarly onset (within 48 hrs)Sensation intactproximal > distal weakness

  • Critical Illness Polyneuropathy (CIP):
    • Nerve involvementDistal > proximal weakness, sensory deficits
    • Critical Illness Polyneuromyopathy (CIPNM): Combination of both

    Diagnosis

    • Medical Research Council Score (MRC-SS):
      • Score < 48: ICU-AW
      • Score < 36: severe ICU-AW
    • Handgrip dynamometry: <11 kg (men), <7 kg (women)
    • Electrophysiology: EMG/NCS to distinguish CIM vs CIP
    • Muscle ultrasound: bedside monitoring
    • MRI/CT/Muscle biopsy: rarely used due to practical limitation

    Risk Factors

    Modifiable:

    • Hyper/hypoglycemia
    • Electrolyte derangement
    • Parenteral nutrition
    • Immobility
    • Medications (steroids, NM blockers, sedatives, aminoglycosides)

    Non-modifiable:

    • Age, female sex, comorbidities
    • Severity of illness, prolonged ventilation
    • Sepsis, multi-organ failure

     Management & Prevention

    • Prevention is key:
      • Early treatment of sepsis and inflammation
      • Glycemic control
      • Early enteral nutrition
      • Minimize sedation (A-F bundle)
      • Early mobilization and physical therapy
    • NMES (neuromuscular electrical stimulation): emerging therapy, needs more evidence

    Outcomes

    • Short-term: increased LOS, ventilation duration, mortality
    • Long-term: decreased function, discharge to rehab, prolonged recovery

    Final Takeaways

    Listen Now

    Love PodBriefly?

    If you like Podbriefly.com, please consider donating to support the ongoing development.

    Support Us